Collaborative and Other Arrangements - Additional Information (Details)	3 Months Ended			12 Months Ended
	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2019 USD ($) target	Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, research and development expenses	$ 2,000,000		$ 1,700,000
CRISPR Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, right to exclusively license, number of targets | target				3
Collaborative arrangement, development and regulatory potential milestone payments maximum				$ 410,000,000
CRISPR A&R JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum		$ 200,000,000
Up-front payment		$ 900,000,000
Allocation of net profits and net losses, percent					60.00%
CRISPR A&R JDCA | CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of net profits and net losses, percent					40.00%